Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: N/E PATSFAN who wrote (8674)	7/5/2000 12:38:48 PM
From: Galirayo	Respond to of 9262

[ UTCI ] Cool! I see you found it. They issued stock for Sterling Shareholders recently. They should now fall more into the Semi area ... but no one has noticed yet. That's why I bought it. In addition to them breaking out of the bottom of their regression channel RE: EDIT > biz.yahoo.com I wonder when the FDA will finish the Fast Track on GNLBs Lupus Drug? Anyone know? biz.yahoo.com James A.D. Smith, Genelabs President and Chief Executive Officer said, ``Based on the encouraging results of our two pivotal trials of GL701 for SLE, we recently submitted the clinical sections of the New Drug Application (NDA) for marketing approval in the United States and we are on schedule to submit the remaining sections in the second half of this year. The FDA has granted fast track designation for GL701 and has agreed that our NDA would be submitted on a rolling basis. If approved, GL701 will be the first new treatment for lupus patients in 40 years.'' Ray